Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Feb 23:9:21.
doi: 10.1186/1476-511X-9-21.

Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study

Agata Bielecka-Dabrowa  1 , Jan Henryk Goch, Jacek Rysz, Marek Maciejewski, Ravi Desai, Wilbert S Aronow, Maciej Banach
Affiliations
Randomized Controlled Trial

Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study

Agata Bielecka-Dabrowa et al. Lipids Health Dis. .

Abstract

Introduction: The aim of the study was to assess the influence of co-existing atrial fibrillation (AF) on inflammatory condition factors, left ventricular function, clinical course and the efficacy of statin treatment of congestive heart failure in the course of dilated cardiomyopathy (DCM).

Material and methods: In a prospective, randomized, open-label study, 69 patients with DCM and left ventricular ejection fraction (LVEF) < or =40% were divided into two groups, with and without AF, who were treated according to the recommended standards. 68% of patients from the group with AF and 59% of patients from the group without AF were administered atorvastatin 40 mg daily for 8 weeks and 10 mg for next 4 months. Clinical examination with the assessment of body mass index (BMI) and waist size were followed by routine laboratory tests, measurement of concentration of tumor necrosis factor (TNF-alpha), interleukin-6 (IL-6), and IL-10 in blood plasma, N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in blood serum, echocardiographic examination, and the assessment of exercise capacity in 6-minute walk test (6-MWT). After six months, morbidity rate and the number of heart failure hospitalizations were also observed.

Results: In the whole population of patients, a significantly higher concentration of NT-proBNP was observed in the AF group (2669 +/- 2192 vs 1540 +/- 1067, p = 0.02). After statin treatment, in patients with DCM and co-existing AF, higher values of NT-proBNP and IL-6 were observed compared to non-AF patients (1530 +/- 1054 vs 1006 +/- 1195, p = 0.04 and (14.16 +/- 13.40 vs 6.74 +/- 5.45, p = 0.02, respectively).

Conclusion: In patients with DCM and co-existing AF, a weaker effect of atorvastatin concerning the reduction of IL-6 and NT-proBNP concentration was observed than in patients without atrial fibrillation.

Trial registration: ClinicalTrials.gov NCT01015144.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The comparison of IL-6 level in AF and non-AF patients treated with atorvastatin.
See this image and copyright information in PMC

References

    1. Viswanathan MN, Page RL. Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opin Investig Drugs. 2009;18(4):417–431. doi: 10.1517/13543780902773410. - DOI - PubMed
    1. Aronow WS, Banach M. Atrial Fibrillation: The New Epidemic of the Ageing World. J Atrial Fibrillation. 2009;1:337–361. - PMC - PubMed
    1. Grönefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther. 2003;8(2):107–113. doi: 10.1177/107424840300800203. - DOI - PubMed
    1. Banach M, Kourliouros A, Reinhart KM, Benussi S, Mikhailidis DP, Jahangiri M, Baker W, Galanti A, Rysz J, Camm JA, White CM, Alfieri O. Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol. 2010. in press . - PubMed
    1. Kaski JP, Elliott P. ESC Working Group. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz. 2007;32(6):446–51. doi: 10.1007/s00059-007-3045-5. - DOI - PubMed

Publication types

MeSH terms

Associated data